Chronic liver disease in the hispanic population of the united states

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 10, 2011, Pages 834-841

  Carrion, Andres F ^a   Ghanta, Ravi ^a   Carrasquillo, Olveen ^a   Martin, Paul ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Ethnicity; Fibrosis; Latino; Race; Risk

Indexed keywords

INSULIN SENSITIZING AGENT; INTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PIOGLITAZONE; RIBAVIRIN;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CAUCASIAN; CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DISEASE COURSE; ETHNIC DIFFERENCE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL SPECIALIST; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; PATIENT REFERRAL; PRIMARY BILIARY CIRRHOSIS; REVIEW; TREATMENT OUTCOME;

CHRONIC DISEASE; HISPANIC AMERICANS; HIV; HUMANS; INCIDENCE; LIVER DISEASES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 80053133540     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.04.027     Document Type: Review

References (90)

1. Hispanic population of the United States US Census Bureau, Accessed January 20, 2010. http://www.census.gov/population/www/socdemo/hispanic/hispanic_pop_presentation.html.
2. CDC vital and health statistics: United States life tables by Hispanic origin. Series 2, Number 152 Centers for Disease Control and Prevention, Accessed January 20, 2010. http://www.cdc.gov/nchs/data/series/sr_02/sr02_152.pdf.
3. Morales L.S., Lara M., Kington R.S., et al. Socioeconomic, cultural, and behavioral factors affecting Hispanic health outcomes. J Health Care Poor Underserved 2002, 13:477-503.
4. Sorlie P.D., Backlund E., Johnson N.J., et al. Mortality by Hispanic status in the United States. JAMA 1993, 270:2464-2468.
5. Hummer R.A., Rogers R.G., Amir S.H., et al. Adult mortality differentials among Hispanic subgroups and non-Hispanic whites. Soc Sci Q 2000, 81:459-476.
6. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2006 Centers for Disease Control and Prevention, CDC, Accessed January 20, 2010. http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_14.pdf.
7. National Center for Health Statistics. Health Data Interactive Centers for Disease Control and Prevention, Accessed August 10, 2010. http://www.cdc.gov/nchs/hdi.htm.
8. Vong S., Bell B.P. Chronic liver disease mortality in the United States, 1990-1998. Hepatology 2004, 39:476-483.
9. Singh G.K., Hoyert D.L. Social epidemiology of chronic liver disease and cirrhosis mortality in the United States, 1935-1997: trends and differentials by ethnicity, socioeconomic status, and alcohol consumption. Hum Biol 2000, 72:801-820.
10. Nguyen G.C., Thuluvath P.J. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology 2008, 47:1058-1066.
11. Kemmer N., Neff G.W. Ethnic variations in chronic liver diseases. Dig Dis Sci 2008, 53:1339-1344.
12. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
13. Yang A.L., Vadhavkar S., Sing G., et al. Epidemiology of alcohol-related liver and pancreatic disease in the United States. Arch Intern Med 2008, 168:649-656.
14. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
15. Wasley A., Kruszon-Moran D., Kuhnert W., et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010, 202:192-201.
16. Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010, 59:517-520. Centers for Disease Control and Prevention (CDC).
17. Davila J.A., El-Serag H.B. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006, 4:104-110.
18. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
19. Cheung O., Sanyal A.J. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009, 25:230-237.
20. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl 1):S5-S10.
21. Schwimmer J.B., McGreal N., Deutsch R., et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005, 115:e561-e565.
22. Mohanty S.R., Troy T.N., Huo D., et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009, 50:797-804.
23. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
24. Gholam P.M., Flancbaum L., Machan J.T., et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408.
25. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
26. Guerrero R., Vega G.L., Grundy S.M., et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 2009, 49:791-801.
27. Alazmi W.M., Regev A., Molina E.G., et al. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006, 51:1725-1729.
28. Kallwitz E.R., Guzman G., TenCate V., et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol 2009, 104:64-69.
29. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
30. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
31. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
32. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
33. Pekmezi D.W., Neighbors C.J., Lee C.S., et al. A culturally adapted physical activity intervention for Latinas: a randomized controlled trial. Am J Prev Med 2009, 37:495-500.
34. Lopez-Quintero C., Berry E.M., Neumark Y. Limited English proficiency is a barrier to receipt of advice about physical activity and diet among Hispanics with chronic diseases in the United States. J Am Diet Assoc 2009, 109:1769-1774.
35. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
36. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplant 2001, 7:363-373.
37. Kim W.R., Brown R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
38. CDC/NCHS National Health Interview Survey, 1997-2009, Sample Adult Core component, Accessed December 8, 2010. http://www.cdc.gov/nchs/data/nhis/earlyrelease/201006_09.pdf.
39. Mandayam S., Jamal M.M., Morgan T.R. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004, 24:217-232.
40. Lee D.J., Markides K.S., Ray L.A. Epidemiology of self-reported past heavy drinking in Hispanic adults. Ethn Health 1997, 2:77-88.
41. Zemore S.E. Acculturation and alcohol among Latino adults in the United States: a comprehensive review. Alcohol Clin Exp Res 2007, 31:1968-1990.
42. Caetano R., Ramisetty-Mikler S., Rodriguez L.A. The Hispanic Americans Baseline Alcohol Survey (HABLAS): the association between birthplace, acculturation and alcohol abuse and dependence across Hispanic national groups. Drug Alcohol Depend 2009, 99:215-221.
43. Stewart S.H. Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 2002, 162:2236-2239.
44. Mendenhall C.L., Gartside P.S., Roselle G.A., et al. Longevity among ethnic groups in alcoholic liver disease. Alcohol Alcohol 1989, 24:11-19.
45. Yoon Y.H., Yi H.Y., Thompson P.C. Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res 2011, 35:240-249.
46. Schmidt L.A., Ye Y., Greenfield T.K., et al. Ethnic disparities in clinical severity and services for alcohol problems: results from the national alcohol survey. Alcohol Clin Exp Res 2007, 31:48-56.
47. Field C.A., Caetano R., Harris T.R., et al. Ethnic differences in drinking outcomes following a brief alcohol intervention in the trauma care setting. Addiction 2010, 105:62-73.
48. Field C., Caetano R. The role of ethnic matching between patient and provider on the effectiveness of brief alcohol interventions with Hispanics. Alcohol Clin Exp Res 2010, 34:262-271.
49. Ananthakrishnan A.N., Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008, 103:901-910.
50. Surveillance for Acute Viral Hepatitis - United States Centers for Disease Control and Prevention, Accessed: June 12, 2010. http://www.cdc.gov/mmwr/pdf/ss/ss5803.pdf.
51. Murphy E.L., Bryzman S., Williams A.E., et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996, 275:995-1000.
52. Nainan O.V., Alter M.J., Kruszon-Moran D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006, 131:478-484.
53. Diaz T., Des Jarlais D.C., Vlahov D., et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001, 91:23-30.
54. Trooskin S.B., Navarro V.J., Winn R.J., et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 2007, 13:1074-1078.
55. Verma S., Bonacini M., Govindarajan S., et al. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006, 101:1817-1823.
56. Kallwitz E.R., Layden-Almer J., Dhamija M., et al. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol 2010, 8:72-78.
57. Cheung R.C., Currie S., Shen H., et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005, 100:2186-2193.
58. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009, 360:257-267.
59. Yu S., Douglass J.M., Qualls C., et al. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in Hispanics compared to non-Hispanic whites. Am J Gastroenterol 2009, 104:1686-1692.
60. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
61. Mathur A.K., Schaubel D.E., Gong Q., et al. Racial and ethnic disparities in access to liver transplantation. Liver Transplant 2010, 16:1033-1040.
62. Gish R.G., Gadano A.C. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006, 13:787-798.
63. Kato H., Gish R.G., Bzowej N., et al. Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. J Med Virol 2004, 73:516-521.
64. Goldstein S.T., Alter M.J., Williams I.T., et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implications for vaccination programs. J Infect Dis 2002, 185:713-719.
65. Hepatitis B vaccination coverage among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 2006, 55:509-511. Centers for Disease Control and Prevention (CDC).
66. Nair S., Eustace J., Thulu-vath P.J. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002, 359:287-293.
67. Alberti A., Clumeck N., Collins S., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
68. Estrada A.L. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002, 117(Suppl 1):e126-e134.
69. Fisher D.G., Reynolds G.L., Jaffe A., et al. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J Addict Dis 2006, 25:25-32.
70. Kim J.H., Psevdos G., Suh J., et al. Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. World J Gastroenterol 2008, 14:6689-6693.
71. Gaslightwala I., Bini E.J. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006, 44:1026-1032.
72. McGovern B.H., Ditelberg J.S., Taylor L.E., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006, 43:365-372.
73. Sherman K.E., Anderson J.W., Butt A.A., et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010 Oct 1, [Epub ahead of print].
74. El-Serag H.B., Lau M., Eschbach K., et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007, 167:1983-1989.
75. Wong R., Corley D.A. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med 2008, 121:525-531.
76. Perez A., Anzaldua M., McCormick J., et al. High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population. J Gastroenterol Hepatol 2004, 19:289-295.
77. Widjaja D., Yarlagadda S., Singu B.S., et al. Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. J Natl Med Assoc 2007, 99:384-388.
78. El-Serag H.B., Siegel A.B., Davila J.A., et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006, 44:158-166.
79. Siegel A.B., McBride R.B., El-Serag H.B., et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008, 103:120-127.
80. Czaja A.J. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:379-388.
81. Czaja A.J. Autoimmune liver disease. Curr Opin Gastroenterol 2009, 25:215-222.
82. Pando M., Larriba J., Fernandez G.C., et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999, 30:1374-1380.
83. Czaja A.J., Souto E.O., Bittencourt P.L., et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002, 37:302-308.
84. Fainboim L., Cañero Velasco M.C., Marcos C.Y., et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001, 33:1512-1517.
85. Bahar R.J., Yanni G.S., Martín M.G., et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001, 72:829-833.
86. Peters M.G., Di Bisceglie A.M., Kowdley K.V., et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007, 46:769-775.
87. Vázquez-Elizondo G., Ponciano-Rodríguez G., Uribe M., et al. Human leukocyte antigens among primary biliary cirrhosis patients born in Mexico. Ann Hepatol 2009, 8:32-37.
88. Bowlus C.L., Li C.S., Karlsen T.H., et al. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transplant 2010, 16:1324-1330.
89. Futagawa Y., Terasaki P.I. An analysis of the OPTN/UNOS liver transplant registry. Clin Transpl 2004, 315:329.
90. Kemmer N., Neff G.W. Liver transplantation in the ethnic minority population: challenges and prospects. Dig Dis Sci 2010, 55:883-889.